The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel
The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‑based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‑based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
This guideline updates diagnosis, risk stratification and therapeutic recommendations for myelofibrosis, incorporating new JAK‑inhibitor approvals, molecular risk scores, and a patient‑reported symptom assessment tool. Clinicians can use these recommendations to tailor treatment, consider early transplantation, and improve patient outcomes.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- Current treatments, practical management, and emerging investigational therapies for myelofibrosis